Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
ALK – anaplastic lymphoma kinase – is an important biomarker found in NSCLC, and targeted therapies have been shown to dramatically improve progression-free survival compared to the previous standard of care(2,3,4). The VENTANA ALK (D5F3) CDx Assay(5) is now FDA approved as a companion diagnostic in four targeted treatments, providing more options to lung cancer patients